BPG is committed to discovery and dissemination of knowledge
Articles in Press
1/28/2026 5:38:28 AM | Browse: 6 | Download: 0
Publication Name World Journal of Diabetes
Manuscript ID 115771
Country Spain
Category Endocrinology & Metabolism
Manuscript Type Prospective Study
Article Title Impact of visceral adiposity on glycemic variability in insulin-treated type 2 diabetes patients undergoing hemodialysis
Manuscript Source Unsolicited Manuscript
All Author List Pedro Gil-Millán, Ascensión Lupiañez, Sonia Caparrós, Alicia Ribas, Shaira Martínez-Vaquera, Ángel Ortiz-Zuñiga, Cristina Hernández, Rafael Simó and Olga Simó-Servat
Funding Agency and Grant Number
Corresponding Author Pedro Gil-Millán, MD, Department of Endocrinology, Hospital Vall d´Hebron, Paseo de la Vall d'Hebron, 119-129, Barcelona 08035, Catalonia, Spain. pedroalejandro.gil@vallhebron.cat
Key Words Type 2 diabetes; Hemodialysis; Visceral adiposity; Continuous glucose monitoring; Time in range; Glycemic stability; Body composition; Metabolic fragility
Core Tip We conducted a prospective study using twenty days of continuous glucose monitoring to better understand glycemic instability in insulin-treated type 2 diabetes patients undergoing hemodialysis. Our results show that low visceral fat area is a strong and independent determinant of larger fluctuations in time-in-range between dialysis and non-dialysis days. Patients with low visceral adiposity had higher mean glucose, lower time-in-range, and more pronounced post-dialysis hyperglycemia. Visceral fat was the only variable that remained significant after multivariate adjustment. These findings suggest that visceral adiposity may act as a metabolic buffer, and that patients with low visceral fat area represent a fragile phenotype who may benefit from closer monitoring and more personalized diabetes management in the hemodialysis.
Citation Gil-Millán P, Lupiañez A, Caparrós S, Ribas A, Martínez-Vaquera S, Ortiz-Zuñiga Á, Hernández C, Simó R, Simó-Servat O. Impact of visceral adiposity on glycemic variability in insulin-treated type 2 diabetes patients undergoing hemodialysis. World J Diabetes 2026; In press
Received
2025-10-25 08:49
Peer-Review Started
2025-10-31 00:57
First Decision by Editorial Office Director
2025-11-25 07:49
Return for Revision
2025-11-25 07:49
Revised
2025-12-04 10:32
Publication Fee Transferred
2025-12-17 07:15
Second Decision by Editor
2026-01-21 02:40
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director
2026-01-28 05:38
Articles in Press
2026-01-28 05:38
Edit the Manuscript by Language Editor
Typeset the Manuscript
ISSN 1948-9358 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com